MVZ

EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN

Retrieved on: 
Thursday, May 4, 2023
MVZ, Partnership, Clinic, Cancer, Diagnosis, Quality of life, Football Manager 2020, Brain, Research, Prostate, Radiation therapy, Mediclinic International, Radiation, Hospital, Interventional radiology, Acquisition, Patient, Palliative care, CFO, Medical imaging, Nursing

MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN

Key Points: 
  • MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
    The issuer is solely responsible for the content of this announcement.
  • Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
    Robert Janker Klinik is specialised in radiotherapy, interventional radiology and palliative care.
  • The transaction includes the replacement of all equipment in the clinic to deliver state-of-the-art diagnostics and oncology related treatments.
  • MEDICLIN has found the right partner in Mercurius Health for the further development of the clinic, which specialises in minimally invasive diagnostics and cutting-edge oncology therapies.

Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel

Retrieved on: 
Friday, April 14, 2023
Technology, Medical Devices, Clinical Trials, Health Technology, Software, Other Health, Biotechnology, Hardware, Health, Consumer Electronics, Transfer, Infection, MVZ, MYT, Gastroenteritis, MALDI, BRKR, Workflow, HT, Mycobacterium, PCR, Multimedia, Temperature, Fungus, DK, Congress, Gastrointestinal tract, ECCMID, Nontuberculous mycobacteria, Partner, XT, Laboratory, European, IVD, MBT, Microbiology, Bruker, Vaccine, Medical device

The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.

Key Points: 
  • The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.
  • The MBT Mycobacteria IVD Kit further simplifies the workflow for identification of nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on time.
  • The new LiquidArray® Gastrointestinal is a syndromic panel that enables the simultaneous detection of up to 26 pathogens causing gastroenteritis.
  • The new LiquidArray® Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage.

Philips highlights FetView cloud-based image sharing and reporting software for obstetrics and gynecology at ISUOG 2022

Retrieved on: 
Thursday, September 15, 2022
Software, Workflow, Prenatal care, Efficiency, Philips, NYSE, PHG, Program, Pregnancy, Patient, EPIQ, AEX, Physician, MVZ, Â, Solution, Affinity analysis, DICOM, International Society, Documentation, PDF, International Society of Ultrasound in Obstetrics and Gynecology, Communication, World Congress, Medical imaging, Gynaecology, Ultrasound, Obstetrics

Philips Fetview is an integrated solution that combines fetal ultrasound imaging with enhanced reporting and easy access to an expectant mothers medical data and fetal images.

Key Points: 
  • Philips Fetview is an integrated solution that combines fetal ultrasound imaging with enhanced reporting and easy access to an expectant mothers medical data and fetal images.
  • By enabling full digitalization of OB/GYN workflows and patient management, Philips FetView will help drive greater departmental efficiency, reduce costs, and provide a better patient and staff experience.
  • The cloud-based reporting and image sharing capabilities of Philips FetView enhance remote communication between physicians and patients, said Matthijs Groot Wassink, General Manger, OB/GYN Ultrasound at Philips.
  • Philips FetView will be featured with additional Philips OB/GYN solutions helping to drive earlier and more definitive diagnoses being showcased at this years International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) World Congress (September 16 18, 2022, London, U.K.).

DGAP-News: RHÖN-KLINIKUM AG looks back on successful financial year 2021

Retrieved on: 
Friday, April 1, 2022
EBITDA, 2009 Davis Cup, Company, Asclepius, Giessen, Investment, Group, University, Legislation, Board, Letter, MVZ, Education, Research, Hospital, Workload, Nursing, Investor, Hesse, Consolidated, Federalism, Person, Hope, Intention, COVID-19, DRG, Patient, Partnership, Medicine, Health insurance

For RHN-KLINIKUM AG, financial year 2021 was also marked by the COVID-19 pandemic and a big test of its strength and resilience.

Key Points: 
  • For RHN-KLINIKUM AG, financial year 2021 was also marked by the COVID-19 pandemic and a big test of its strength and resilience.
  • In financial year 2021, revenues grew by 3.1 per cent to reach 1.4 billion.
  • For the current financial year, we expect revenues of 1.4 billion euros within a range of plus or minus 5 per cent.
  • RHN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA.

DGAP-News: Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

Retrieved on: 
Tuesday, February 15, 2022
NASDAQ, Health, Colorectal cancer, Adoption, Cross channel, Patient, FIT, Cancer, Biomarker, Laboratory, Prospectus, Company, News, Polymerase chain reaction, SEC, Forward-looking statement, U.S. Securities and Exchange Commission, Solution, PCR, Neoplasm, Death, Private Securities Litigation Reform Act, American Cancer Society, Security (finance), Awareness, Real-time polymerase chain reaction, Compliance, Large intestine, FDA, Partnership, Colon, Marketing, Ageing, Physician, Labour, DNA, COVID-19, CRC, Trial of the century, DGAP, MVZ, IVDR, Pharmaceutical industry, Vaccine, EU, ColoAlert, Colorectal Cancer, Mainz Biomed N.V., COLOALERT, COLORECTAL CANCER, MAINZ BIOMED N.V.

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mnchengladbach

Key Points: 
  • Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mnchengladbach
    The issuer is solely responsible for the content of this announcement.
  • Laboratory Mnchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomed's unique, highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).
  • "As an organization focused on delivering the very best diagnostics solutions to our network, we've been highly impressed by the efficacy of the ColoAlert test.
  • ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*.

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

Retrieved on: 
Monday, February 14, 2022
NASDAQ, Health, Colorectal cancer, Adoption, Cross channel, Patient, FIT, Cancer, Biomarker, Laboratory, Prospectus, Â, Company, Polymerase chain reaction, SEC, Forward-looking statement, U.S. Securities and Exchange Commission, Solution, Neoplasm, PCR, Death, Private Securities Litigation Reform Act, American Cancer Society, Security (finance), Awareness, Real-time polymerase chain reaction, GLOBE, Compliance, Large intestine, FDA, Partnership, Colon, Ageing, Marketing, Physician, Labour, DNA, COVID-19, CRC, Trial of the century, MVZ, IVDR, Pharmaceutical industry, Medical device, Vaccine, EU

Laboratory Mnchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomeds unique, highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).

Key Points: 
  • Laboratory Mnchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomeds unique, highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).
  • Under the terms of the partnership, Mainz Biomed will co-brand ColoAlert with Laboratory Mnchengladbach, and sell its polymerase chain reaction (PCR) assay kits for advanced colorectal cancer detection, on an on-demand basis for use by Labor Mnchengladbachs network of physicians and their patients.
  • As an organization focused on delivering the very best diagnostics solutions to our network, weve been highly impressed by the efficacy of the ColoAlert test.
  • ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*.

Global Li-Ion Graphite Completes Field Work and Welcomes Mr. Bill Feyerabend and Mr. Vincente Herrera to the Companies Advisory Board

Retrieved on: 
Wednesday, November 18, 2020
MVZ

The four-day due diligence program of Global Li-Ions MVZ Project in Chihuahua, Mexico was completed on October 20.

Key Points: 
  • The four-day due diligence program of Global Li-Ions MVZ Project in Chihuahua, Mexico was completed on October 20.
  • Finally Analyses of 42 field samples taken of the mineralization and altered rock are expected in about three weeks.
  • This work will assist in designing the next stages of exploration and specifically geophysical surveying to define drill targets.
  • In addition, we are very excited to have Bill and Vincente join our Advisory Board.

German Accreditation of Laboratory Developed Tests on Bionano’s Saphyr System Accelerates Utilization in Clinical Diagnostics

Retrieved on: 
Thursday, September 24, 2020
Branches of biology, Genetics, Biology, Chromosomes, Cytogenetics, Chromosomal abnormalities, Structural variation, Gene duplication, Chromosomal translocation, Accreditation, Chromosomal inversion, MVZ

The approval accredits LDTs developed by MVZ Martinsried for the detection of the following types of structural variants (SVs): translocations, inversions and duplications.

Key Points: 
  • The approval accredits LDTs developed by MVZ Martinsried for the detection of the following types of structural variants (SVs): translocations, inversions and duplications.
  • Inversions and duplications are also often implicated in cancers and all three types are known to occur in constitutional genetic disorders.
  • "MVZ Martinsrieds receipt of this first European accreditation for use of Saphyr-based LDTs is an important milestone towards broader accreditation and adoption across Europe and other regions.
  • Achieving this accreditation in Germany, the largest market in Europe, is also significant because the German accreditation process follows a very high standard," said Erik Holmlin, chief executive officer of Bionano Genomics.

Global Li-Ion Signs Letter Agreement to Acquire Past Producing Silver-Gold Property Chihauhau State Mexico

Retrieved on: 
Tuesday, September 22, 2020
Geology, Economic geology, Pegmatite, Metasomatism, MVZ, Propylitic alteration, Pajarito, System for Electronic Document Analysis and Retrieval

The 1200 hectare Property hosts 3 past producing silver-gold deposits, El Moro, La Virginia and La Zorra (MVZ Property).

Key Points: 
  • The 1200 hectare Property hosts 3 past producing silver-gold deposits, El Moro, La Virginia and La Zorra (MVZ Property).
  • The Pajarito Project covers a large mineral system with widespread epithermal mineralization and multiple examples of porphyry-style potassic and propylitic alteration.
  • The MVZ Mine Property, based on aero magnetics and pegmatitic quartz on a dump, is interpreted to be located over an intrusive.
  • Further information about Global Li-Ion is available under its profile on the SEDAR website, www.sedar.com , on the CSE website, www.thecse.com , and the Companys website, www.globalli-iongraphite.com .